Please assess the completion status of the following clinical trial:

Trial Title: Study to Assess Efficacy and Safety of Aclidinium Bromide and Aclidinium Bromide/Formoterol Fumarate in Stabile COPD Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* 1. Adult male or non-pregnant, non-lactating female patients aged ≥40~* 2. Patients with a diagnosis of COPD prior to Visit 1 (screening)~* 3. Patients with moderate to severe stable COPD (Stage II or Stage III) at Visit 1: post-bronchodilator FEV1 ≥30% and \< 80% and post-bronchodilator FEV1/Forced vital capacity (FVC) \< 70%~* 4. Current or former smokers with a smoking history of ≥ 10 pack-years~* 5. Patients able to perform repeatable pulmonary function testing for FEV1 according to the American Thoracic Society (ATS)/European Respiratory Society (ERS) 2005 criteria at Visit 1(screening)~* 6. Patients who understand the study procedures and are willing to participate in the study as indicated by signing the informed consent~Exclusion Criteria:~* 1. Involvement in the planning and/or conduct of the study (applies to AstraZeneca staff and/or site staff) or patients employed by or relatives of the employees of the site or sponsor.~* 2. Previous enrolment or randomisation in the present study~* 3. History or current diagnosis of asthma~* 4. Any respiratory tract infection (including the upper respiratory tract) or COPD exacerbation (including the mild COPD exacerbation) within 6 weeks prior to screening or during the run-in period~* 5. Patients hospitalized for COPD exacerbation (an emergency room visit for longer than 24 hours will be considered a hospitalization) within 3 months prior to screening and during the run-in period~* 6. Clinically significant respiratory conditions other than COPD~* 7. Patients who in the Investigator's opinion may need to start a pulmonary rehabilitation program during the study and/or patients who started/finished it within 3 months prior to screening~* 8. Use of long-term oxygen therapy (≥15 hours/day)~* 9. Patient who does not maintain regular day/night, waking/sleeping cycles including night shift workers~* 10. Clinically significant cardiovascular conditions~* 11. Patients with Type I or uncontrolled Type II diabetes, uncontrolled hypo-or hyperthyroidism, hypokalaemia, or hyperadrenergic state, uncontrolled or untreated hypertension~* 12. Patients with QT corrected interval (QTc) using Fridericia formula (QTcF) (QTc=QT/ Duration in milliseconds between two R peaks of two consecutive QRS complexes (RR1/3) \>470 msec as indicated in the centralised reading report assessed at Screening (Visit 1)~* 13. Patients with clinically significant abnormalities in the clinical laboratory tests, ECG parameters (other than QTcF) or in the physical examination at Visit 1 (screening)~* 14. Patients with abnormal liver function tests defined as Aspartate aminotransferase (AST), Alanine aminotransferase (ALT), or total bilirubin ≥ 2.5 times upper limit of normal ranges at screening~* 15. Patient with known non-controlled history of infection with human immunodeficiency virus and/or active hepatitis~* 16. Patient with a history of hypersensitivity reaction to inhaled anticholinergic drugs, sympathomimetic amines, inhaled medication or any component thereof~* 17. Patient with known narrow-angle glaucoma, symptomatic bladder neck obstruction, acute urinary retention, or patients with symptomatic non-stable prostatic hypertrophy~* 18. History of malignancy of any organ system (including lung cancer), treated or untreated, within the past 5 years other than basal or squamous cell skin cancer~* 19. Any other serious or uncontrolled physical or mental dysfunction~* 20. Patients with a history (within 2 years prior to Visit 1 (screening) of drug and/or alcohol abuse that may prevent study compliance based on the Investigator judgment~* 21. Patients unlikely to be cooperative or cannot comply with the study procedures~* 22. Patients treated with any investigational drug within 30 days (or 6 half-lives, whichever is longer) prior to screening~* 23. Patients who intended to use any concomitant medication not permitted by this protocol or who had not undergone the required washout period for a particular prohibited medication~* 24. Patients unable to give consent, or patients of consenting age but under guardianship, or vulnerable patients~* 25. Any other conditions that, in the Investigator's opinion, might have indicated the patient to be unsuitable for the study

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 130 Years
- Healthy Volunteers: f

Study Arms:
- Experimental 1 (Type: EXPERIMENTAL): Aclidinium bromide 400μg/Formoterol fumarate 12 μg
- Experimental 2 (Type: EXPERIMENTAL): Aclidinium bromide 400 μg
- Comparator (Type: ACTIVE_COMPARATOR): Formoterol fumarate 12 μg
- Placebo (Type: PLACEBO_COMPARATOR): Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete